|
Management
The LeukoSight,
Inc. management team is made up
of leading scientists in the areas of inflammation and immunity. They
developed LeukoSight's proprietary technology in collaboration with the
University of Maryland:
David Mosser, PhD, Founder & CEO.
Professor and
Director of the Laboratory of Macrophage Biology at the University of Maryland and Past-President of
the Society for Leukocyte Biology. He is a member of the NIH, NIAID Board
of Scientific Counselors and an editorial board member of four journals
pertaining to immunity and inflammation. The author of more than hundred articles, Dr. Mosser is a
leader in this field.
Xia, Zhang, MD, PhD, President.
Research Assistant Professor at UMD and author of more than 25 articles on
inflammatory cytokines. He is a former Parke-Davis young scientist award
winner and reviewer for the Broad Foundation. He is a regular reviewer
for the Journal of Biological Chemistry.
Shanjin Cao, MD, PhD,
Chief Scientific Officer Research Assistant Professor at UMD and
author of more than 20 publications and chapters on the transcriptional
regulation of cytokine genes. He is a regular reviewer for the Journal of
Immunology and the Journal of Leukocyte Biology.
Board of Directors ...LeukoSight's
Board of Directors complements the companys scientific leadership with
strong business and investment insights. In addition to Dr. Mosser, board
members are:
Steven Burke, MD Chief Medical Officer,
Proteon Therapeutics. Former Senior Vice President
of Regulatory Affairs at Genzyme. He developed Renagel and Welchol as VP
of clinical research at GelTex Pharmaceuticals.
Mark Grovic, Esq. ...Managing
Director and Co-founder of the New Markets Growth Fund. Former
portfolio manager or director with four other investment funds, including
the Calvert Group. He serves on multiple investment committees, including MAVAs Selection Committee and TEDCO. |
